Company Overview and News
2018-09-11 reuters - 3
BERLIN (Reuters) - German artificial limb manufacturer Ottobock plans to start selling a mechanical exoskeleton that makes manual labor for factory workers easier this week, joining a field already crowded with major industrial players and start-ups.
2018-08-21 sec.gov - 2
PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5)
2018-08-21 sec.gov - 1
2018-08-15 globenewswire - 1
RICHMOND, Calif., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that U.S. government’s General Services Administration (GSA) has added the company to its list of contracted Federal Business Opportunities (FBO).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION W
2018-08-13 globenewswire - 4
RICHMOND, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that John (Jack) Glenn has been appointed to the position of Chief Financial Officer. Mr. Glenn brings over 25 years of financial leadership experience within public and private companies in the life sciences industry.
2018-08-09 seekingalpha - 3
Array BioPharma (ARRY) announced that the combination of BRAFTOVI (encorafenib), MEKTOVI (binimetinib) and Eli Lilly's (LLY) ERBITUX (cetuximab) is now an FDA-designated Breakthrough Therapy for the treatment of patients with BRAF V600E mutation-positive metastatic colorectal cancer (‘mCRC) after the failure of one or two prior lines of treatment for metastatic cancer.
BOLD BLPH MNOV EKSO ARRY ONCE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-08-07 bloomberg - 3
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-07-31 globenewswire - 1
RICHMOND, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2018 after the close of trading on Tuesday, August 7, 2018. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
2018-07-27 investorplace - 5
With automated technologies, the domain of fantasy and science-fiction is steadily becoming not only reality, it’s becoming the new norm. The robotic revolution has dramatically altered the economic landscape, driving productivity primarily in manufacturing and in many other sectors. As a result, automation stocks are virtual necessities for your portfolio.
LMT MIDD A CGNX CTRL ISRG EKSO ABB TER HON AAPL EMR OII BRKS ROK
2018-07-10 sec.gov - 6
Filed Pursuant to Rule 424(b)(5) Registration No. 333-218517 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2017)
2018-07-10 sec.gov - 11
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EKSO / Ekso Bionics Holdings, Inc. on message board site Silicon Investor.
|EKSO Bio||EKSO Bio||EKSO Bio|
as of ET